GSM-779690T
Oral gamma-secretase modulator in Phase 1 for early Alzheimer's intervention
actapharmaceuticals.com/gsm-779690t
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
GSM-779690T is Acta Pharmaceuticals' lead investigational oral gamma-secretase modulator designed to reduce longer amyloid-beta forms such as Aβ42 while increasing shorter forms including Aβ37 and Aβ38. It is in a Phase 1 study in healthy adult participants (ClinicalTrials.gov NCT07690228), building on research from Massachusetts General Hospital, Harvard Medical School and UC San Diego collaborators.
- Added via
- web
- Ownership
- unclaimed
Where to go
For people
- Homepageactapharmaceuticals.com/gsm-779690t
- ClinicalTrials.govclinicaltrials.gov/study/NCT07690228
For agents
Nothing listed yet.
Product details
- Product kind
- Other